O
HALO icon

OrbiMed’s Halozyme HALO Stock Holding History

OrbiMed’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-350,000
Closed -$6.08M – 137
2017
Q3 		$6.08M Hold
350,000
– – 0.06% 119
2017
Q2 		$4.49M Buy
+350,000
New +$4.67M 0.05% 117

Other funds holding HALO

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OrbiMed's HALO Position: Q4 2017 in Review

OrbiMed sold out of Halozyme (HALO) in Q4 2017, closing a stake of 350,000 shares — an estimated $6.08M sold.

OrbiMed first reported a position in HALO in Q2 2017 and held it in 2 quarters. The position peaked at $6.08M in Q3 2017. 198 funds tracked by Wall St. Rank hold HALO as of Q4 2017.

  • OrbiMed reported no remaining Halozyme position as of Q4 2017 after selling out during the quarter.
  • OrbiMed sold 350,000 Halozyme shares in Q4 2017, an estimated $6.08M.
  • OrbiMed first reported a position in Halozyme in Q2 2017 and held it in 2 quarters.
  • OrbiMed's Halozyme position peaked at $6.08M in Q3 2017.
  • 198 funds tracked by Wall St. Rank held Halozyme as of Q4 2017.

Based on OrbiMed's 13F filing for Q4 2017, filed 14 Feb 2018.